NeuroPace, Inc. Price & Performance (NPCE)

NeuroPace has received renewed optimism from analysts, with several maintaining Buy ratings and price targets as high as $20, despite the stock’s recent 2% dip this year. The company’s Q4 earnings beat expectations, and consensus suggests significant upside, though insider sentiment has turned negative due to increased share sales.12

Company officials state recently implemented tariffs will have minimal impact on operations or margins, as most manufacturing and sales occur in the U.S. NeuroPace reiterated its 2025 gross margin guidance and confirmed wind-down of its SEEG distribution deal, with no change to revenue projections or long-range growth plans.34

Technical analysis indicates NeuroPace shares remain in a broad, declining trend, with a projected 20% drop possible over the next three months. While short-term buy signals have emerged, the overall outlook remains negative, and analysts advise caution due to ongoing volatility and low trading volume.56